NCT05256446

Brief Summary

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 25, 2022

Completed
Last Updated

September 23, 2024

Status Verified

August 1, 2024

First QC Date

February 15, 2022

Last Update Submit

September 19, 2024

Interventions

AMG 701DRUG

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2022

First Posted

February 25, 2022

Last Updated

September 23, 2024

Record last verified: 2024-08